4'-phenyl-4-methyl-3-nitrobiphenyl | 1303573-65-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-phenyl-4-methyl-3-nitrobiphenyl
• 英文别名: 1-Methyl-2-nitro-4-(4-phenylphenyl)benzene；1-methyl-2-nitro-4-(4-phenylphenyl)benzene
• CAS: 1303573-65-0
• 化学式: C₁₉H₁₅NO₂
• 分子量: 289.334
• InChiKey: VCHKEKZZLXLBLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  草酸二甲酯 、 4'-phenyl-4-methyl-3-nitrobiphenyl 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 生成 methyl 3-(3-nitro-[1,1':4',1''-terphenyl]-4-yl)-2-oxopropanoate
  参考文献：
  名称：

  N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation

  摘要：

  Current cancer research is being increasingly focused on the study of distinctive characters of tumour metabolism, resulting in a switch from oxidative phosphorylation to glycolysis (Warburg effect). Isoform 5 of human lactate dehydrogenase (hLDH5), which catalyzes the final step in the glycolytic cascade (pyruvate to lactate), constitutes a relatively new and untapped anti-cancer target. In this study, careful design and synthesis of a selected series of aryl-substituted N-hydroxyindole-2-carboxylates (NHIs) has led to several hLDH5-inhibitors, showing "first-in-class" potency and isoform selectivity. Enzyme kinetics studies indicated that these inhibitors exhibit a competitive mode of inhibition. Some representative examples were tested against two human pancreatic carcinoma cell lines, and displayed a good antiproliferative activity, which was even more evident under hypoxic conditions. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.08.046
• 作为产物：
  描述：

  4-溴-2-硝基甲苯 、 4-联苯硼酸 在 四丁基溴化铵 、 palladium diacetate 、 sodium carbonate 作用下， 以 水 为溶剂， 反应 0.33h， 以89%的产率得到4'-phenyl-4-methyl-3-nitrobiphenyl
  参考文献：
  名称：

  N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation

  摘要：

  Current cancer research is being increasingly focused on the study of distinctive characters of tumour metabolism, resulting in a switch from oxidative phosphorylation to glycolysis (Warburg effect). Isoform 5 of human lactate dehydrogenase (hLDH5), which catalyzes the final step in the glycolytic cascade (pyruvate to lactate), constitutes a relatively new and untapped anti-cancer target. In this study, careful design and synthesis of a selected series of aryl-substituted N-hydroxyindole-2-carboxylates (NHIs) has led to several hLDH5-inhibitors, showing "first-in-class" potency and isoform selectivity. Enzyme kinetics studies indicated that these inhibitors exhibit a competitive mode of inhibition. Some representative examples were tested against two human pancreatic carcinoma cell lines, and displayed a good antiproliferative activity, which was even more evident under hypoxic conditions. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.08.046

文献信息

• (PER)FLUOROPOLYETHERS WITH bi- OR ter-PHENYL END GROUPS
  申请人：SOLVAY SPECIALTY POLYMERS ITALY S.P.A.

  公开号：US20150011446A1

  公开（公告）日：2015-01-08

  The present invention relates (per)fluoropolyether compounds comprising a (per)fluoropolyether chain (R f ) having at least two chain ends, wherein at least one of said chain ends have a bi- or ter-phenyl group bearing at least one nitro group and, optionally one or more further substituents. The invention also relates to processes for the preparation of such compounds and to their use for the preparation of lubricant compositions in the form of oils or greases.
• [EN] (PER)FLUOROPOLYETHERS WITH bi- OR ter-PHENYL END GROUPS<br/>[FR] (PER)FLUOROPOLYÉTHERS CONTENANT DES GROUPES TERMINAUX BI- OU TER-PHÉNYLE
  申请人：SOLVAY SPECIALTY POLYMERS IT

  公开号：WO2013120827A2

  公开（公告）日：2013-08-22

  The present invention relates (per)fluoropolyether compounds comprising a (per)fluoropolyether chain (Rf) having at least two chain ends, wherein at least one of said chain ends have a bi- or ter-phenyl group bearing at least one nitro group and, optionally one or more further substituents. The invention also relates to processes for the preparation of such compounds and to their use for the preparation of lubricant compositions in the form of oils or greases.
• N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation
  作者：Carlotta Granchi、Sarabindu Roy、Alessio De Simone、Irene Salvetti、Tiziano Tuccinardi、Adriano Martinelli、Marco Macchia、Mario Lanza、Laura Betti、Gino Giannaccini、Antonio Lucacchini、Elisa Giovannetti、Rocco Sciarrillo、Godefridus J. Peters、Filippo Minutolo

  DOI：10.1016/j.ejmech.2011.08.046

  日期：2011.11

  Current cancer research is being increasingly focused on the study of distinctive characters of tumour metabolism, resulting in a switch from oxidative phosphorylation to glycolysis (Warburg effect). Isoform 5 of human lactate dehydrogenase (hLDH5), which catalyzes the final step in the glycolytic cascade (pyruvate to lactate), constitutes a relatively new and untapped anti-cancer target. In this study, careful design and synthesis of a selected series of aryl-substituted N-hydroxyindole-2-carboxylates (NHIs) has led to several hLDH5-inhibitors, showing "first-in-class" potency and isoform selectivity. Enzyme kinetics studies indicated that these inhibitors exhibit a competitive mode of inhibition. Some representative examples were tested against two human pancreatic carcinoma cell lines, and displayed a good antiproliferative activity, which was even more evident under hypoxic conditions. (C) 2011 Elsevier Masson SAS. All rights reserved.